What is MOBILion Systems?
MOBILion Systems operates at the intersection of advanced analytical chemistry and clinical diagnostics. The company specializes in the development of high-resolution instrumentation designed to provide deeper insights into biological samples, thereby facilitating more accurate disease diagnosis and therapeutic development. By leveraging innovative separation science, MOBILion Systems addresses significant bottlenecks in current laboratory workflows. Its market position is bolstered by strong institutional support and strategic partnerships with global leaders in diagnostics, enabling the company to transition from a research-focused entity to a commercial-stage powerhouse capable of delivering scalable solutions to laboratories worldwide.
How much funding has MOBILion Systems raised?
MOBILion Systems has raised a total of $110.8M across 4 funding rounds:
Series A
$15.4M
Debt
$350K
Series B
$35M
Series C
$60M
Series A (2019): $15.4M with participation from Hostplus, iSelect Fund Management, Cultivation Capital, Agilent Technologies, and IP Group Inc.
Debt (2020): $350K led by PPP
Series B (2020): $35M supported by aMoon, IP Group, Hostplus, Cultivation Capital, and Agilent Technologies
Series C (2021): $60M featuring aMoon, Cultivation Capital, IP Group, Hostplus, Agilent Technologies, and D1 Capital Partners
Key Investors in MOBILion Systems
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing laboratories worldwide with advanced instruments, software, consumables, and services.
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology.
IP Group
IP Group is a conglomerate that specializes in intellectual property commercialization, transforming innovative ideas from university partnerships into viable businesses.
What's next for MOBILion Systems?
With the recent influx of capital, MOBILion Systems is poised to transition into a phase of rapid commercial expansion and operational scaling. The strategic focus will likely center on increasing the global footprint of its instrumentation platforms and deepening its integration into clinical and pharmaceutical research environments. As the company matures, the emphasis will shift toward optimizing manufacturing efficiencies and expanding its service ecosystem to support a broader range of diagnostic applications. The continued involvement of high-profile investors suggests a strong confidence in the company's ability to disrupt traditional analytical methodologies and establish a new standard for precision in life sciences.
See full MOBILion Systems company page
